Targeted therapy clinical research of 80 cases of late-stage lung adenocarcinoma

Objective To study the clinical effect of molecular targeted drugs gefitinib in the treatment of the late- stage lung adenocarcinoma. Methods 80 patients of late-stage lung adenocarcinoma from October 2010 to April 2012 were observed,35 cases were given first-line treatment method,45 cases were given the second-line treatment. Patients were given Gefitinib orally,250 mg/d,1 hour after breakfast,served with warm water.If the phenomenon of bone metastases exists,zoledronic acid should be added,"X knife"radiation therapy should be added for patients with brain metastases. Results The cases of CR,PR,SD was 10,15,10 in 35 cases treated with first-line treatment,the median catabatic period was 10 months;the median tumor progression period was 12 months;median follow-up time was 14 months(4-25 months),patients condition was stable;the cases of CR,PR,SDwas 15,10,15 in 45 cases treated with second-line treatment;the median catabatic period was 5.5 months;the median tumor progression period was 6 months;median follow-up time was 12 months(4-31 months),patients condition of 10 cases was stable,5 cases died. Conclusion First-line treatment of gefitinib targeting therapy in late-stage lung adenocarcinoma is superior to second-line treatment,patients have less pain,and treatment process is safe and easy to endure,but because of its expensive price,it is difficult to use and spread with wide range.